NCT06955325 2025-05-06
UPLIFT
The First Affiliated Hospital of Guangzhou Medical University
Phase 3 Not yet recruiting
Clinical Trials
13 trialsNCT01996098 2024-09-05
ICTAN
Sun Yat-sen University
Phase 3 Terminated
NCT06041776 2023-09-22
Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations
Betta Pharmaceuticals Co., Ltd.
Phase 3 Recruiting
NCT02448797 2021-07-20
EVIDENCE
Betta Pharmaceuticals Co., Ltd.
Phase 3 Unknown
NCT04797806 2021-03-15
SAINT
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT04058704 2019-08-15
SMART
Betta Pharmaceuticals Co., Ltd.
Phase 3 Unknown
NCT03992885 2019-06-20
Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT02889692 2019-04-11
Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma
Shanghai University of Traditional Chinese Medicine
Phase 3 Completed
NCT02125240 2018-07-16
ICWIP
Betta Pharmaceuticals Co., Ltd.
Phase 3 Unknown
NCT01724801 2017-03-01
BRAIN
Guangdong Association of Clinical Trials
Phase 3 Completed
NCT02883543 2016-08-30
First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 3 Unknown
NCT02486354 2015-07-01
Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy
Betta Pharmaceuticals Co., Ltd.
Phase 3 Completed
NCT01040780 2014-02-14
ICOGEN
Betta Pharmaceuticals Co., Ltd.
Phase 3 Completed